LMI celebrates SNMMI's Nuclear Medicine and Molecular Imaging Week (October 6 - 12th). This year's theme is "See it. Believe it. Treat it." We want to recognize all of the people who work as physicians, technologists, scientists, and other professionals who care for patients with cognitive impairment to support Alzheimer's disease and dementia detection and research. To order SNMMI-branded merchandise specific to this special week, visit: https://lnkd.in/eaXBM4e9. #nuclearmedicine #SNMMI #NuclearMedicineWeek #Alzheimersdisease #NuclearMedicineandMolecularImagingWeek #LMI #AD #dementia
Life Molecular Imaging
Pharmaceutical Manufacturing
Fareham, England 4,636 followers
www.life-mi.com
About us
Life Molecular Imaging (LMI) is an international pharma company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group – an international people-centered, diversified healthcare organization with four decades of experience in the South African private healthcare sector. To learn more, please visit https://life-mi.com. https://neuraceq.com/wp-content/uploads/USPI-DOC-1118-v5.1-May-2023.pdf
- Website
-
http://www.life-mi.com
External link for Life Molecular Imaging
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Fareham, England
- Type
- Public Company
- Founded
- 2018
- Specialties
- Molecular Imaging, Radiopharmaceuticals, PET/CT, NeuraCeq, Alzheimer's Disease, Amyloid-PET, Tau-PET, florbetaben, and PI-2620
Locations
-
Primary
25 Barnes Wallis Road
Fareham, England PO15 5TT, GB
-
Warwick, Warwickshire CV346DA, GB
-
75 State Street
Floor 1
Boston, Massachusets 02109, US
-
Tegeler Str. 6-7
Berlin, Berlin 13353, DE
Employees at Life Molecular Imaging
Updates
-
#LMI and SOFIE exhibited at the Missouri Valley Chapter (MVC) #SNMMI this past weekend, and our own Applications Specialist, Barbara J. Grabher BS, CNMT, RT(N), NCT, FSNMMI-TS, presented on Understanding Beta-Amyloid, Tau, and the Alzheimer’s Disease Cascade. Also in attendance was our Applications Specialist, Ula Shair T., and Dan Mueller from SOFIE! #Alzheimersdisease #LifeMolecularImaging #MVC #dementia #SocietyofNuclearMedicine #nuclearmedicine #missourichapter #amyloidPET
-
We are delighted to welcome Donna Tom to the LMI team as our new Key Account Manager for New York State. With over 20 years of experience in the pharmaceutical and biotechnology industry, Donna brings a wealth of knowledge and expertise to our organization. Donna has held various sales and management positions throughout her career, representing a diverse portfolio of products ranging from injectables, to immunotherapy, to most recently, PET tracers. Her passion for the healthcare industry and her commitment to delivering exceptional results make her an invaluable asset to our team. During her free time, Donna enjoys exploring new destinations, immersing herself in the great outdoors, and dreams of one day circumnavigating Manhattan by kayak. We are thrilled to have Donna join us! To learn more about career opportunities with us, visit: https://lnkd.in/dSyVHEw #LMI #Careers #PharmaCareers #Pharmaceutical #PharmaceuticalIndustry #SalesJobs #PharmaSales #Alzheimersdisease #AD
-
To round out #HispanicHeritageMonth in September, #LMI participated in the Latino Community Forum on Memory Loss hosted by Alzheimer's Association®’s Greater Maryland Chapter and Howard County Office on Aging and Independence to provide resources and information for family caregivers. LMI's own Katherine Lopez, Ph.D. presented on the importance of early detection of Alzheimer’s disease and the role that biomarkers play in diagnosis. #alzheimersdisease #AD #PETimaging #biomarkers
-
LMI recognizes Down Syndrome Awareness Month (October). In light of this month and our focus at LMI, we’re sharing a fact from the National Down Syndrome Society, and an article about the connection between Down syndrome and Alzheimer's disease (AD) that is linked here, and in the photo below: https://lnkd.in/en5RdbUF. Fact: Chromosome 21 plays a key role in the relationship between Down syndrome and AD. Scientists have located several genes on chromosome 21 that are involved in the aging process and that contribute to the increased risk of AD. To learn more about this month, facts surrounding Down syndrome, and how to get involved, visit: https://lnkd.in/e8Vakqni #DownSyndrome #DownSyndromeAwarenessMonth #Alzheimersdisease #AD #LMI
-
LMI welcomes another new employee, Julie Kim! Julie comes to LMI with 13 years of broad industry knowledge in supply chain, logistics, distribution, and data analysis. She possesses experience in both international and domestic markets with a core focus on vendor relations, supply chain optimization, and distribution efficiency. In Julie's spare time, she likes to spend time with her family. During the summer months (which are sadly behind us), her and her family enjoy visiting the beach. We're happy you joined our growing team, Julie! To learn more about career opportunities with us, visit: https://lnkd.in/dSyVHEw #careeropportunities #supplychain #nuclearmedicine #pharmajobs #LMI #careers #welcome #pharmaceuticalcareers
-
LMI welcomes Leah Jimmerson, Global Regulatory Affairs and Pharmacovigilance Director. Leah has 6 years of regulatory affairs experience representing sponsors to US FDA and supporting strategic drug development in multiple therapeutic areas including oncology, diabetes and obesity disorders, infectious diseases, dermatology, and imaging/diagnostics amongst others. She has led regulatory strategy teams to complete dozens of investigational drug applications and several marketing authorizations in global markets, with an emphasis on the US FDA. Leah has a background in chemistry, biochemistry, and pharmaceutical sciences and strives to support drug development from bench to approval by applying her experience and expertise at every step of development. As a Colorado native, she enjoys the great outdoors and spends her weekends exploring the mountains by hiking, backpacking, camping, and the occasional snowshoe. She looks forward to continuing to represent LMI as regulatory agent to the US FDA and provide key contributions to the development of regulatory strategies for LMI products. We're fortunate to have Leah on board! To learn more about career opportunities with us, visit: https://lnkd.in/dSyVHEw #LMI #Careers #Welcome #pharmaceuticalcareers #nuclearmedicine #salesjobs #Pharmacovigilance #GlobalRegulatoryAffairs
-
#WorldAlzheimersDay, observed every year on September 21st, is meant to raise awareness and challenge the stigma associated with Alzheimer's disease and other forms of dementia. With over 50 million people worldwide living with dementia and millions more being diagnosed each year, it's essential to improve public understanding and provide support for those affected - caregivers included. Here are some tips on overcoming stigma associated with AD and other forms of dementia: https://lnkd.in/evxA7VvY Learn about the history of the disease and how you and your loved ones can observe World AD Day here: https://lnkd.in/erCv-TEk #LMI #WorldADDay #Alzheimersdisease #AD #dementia
-
LMI is dedicated to our work in the Alzheimer's disease space. After decades, there is now hope for patients and families with new therapies, and imaging biomarkers continue to play an important role. LMI is committed to making the invisible visible. We will continue to deliver, maximize, and sustain in this market. To learn more about Life Molecular Imaging, visit our website: https://life-mi.com/ For further details on Neuraceq® (florbetaben F 18 injection) in the US, please refer to the following prescribing information: https://lnkd.in/e5m6HC6m #LifeMolecularImaging #LMI #Neuraceq #florbetaben #alzheimersdisease #demetia #nuclearmedicine
Life Molecular Imaging DELIVER-MAXIMISE-SUSTAIN Joined by Doctor Ludger Dinkelborg and our international colleagues, we delivered the Life Molecular Imaging (“LMI”) Capital Markets Day presentation at the superbly organized RMB - Rand Merchant Bank | Morgan Stanley Big Five Investor Conference in Cape Town this week. We explained in detail how LMI, a wholly owned international subsidiary of Life Healthcare, is fast becoming a prominent player in the global radiopharmaceutical market, developing and selling products used in the diagnosis and treatment of diseases. One LMI product, Neuraceq, already has a significant share of the diagnostic market for Alzheimer’s disease, reporting a c.85% increase in doses sold FY23-FY24. The potential addressable market for Neuraceq is sizeable and could be as much as c. $2.5bn per annum by 2029. We need to deliver and get our share of this market. But there is more to the story we presented … LMI also has an impressive pipeline of 5 potential new products under development - from predicting blood clots and detecting neuroinflammation to treating prostate cancer. We think the markets for the products could exceed $900m in potential annual sales in the future. We have already monetised one product in the portfolio in our previously reported out licensing of RM2 to Lantheus. Now we need to maximise the value in our portfolio across the other products. Sustaining all this activity is the near unique and world class R&D Services and Supplies division of LMI in Germany, not only doing in house research for LMI and creating new products but also providing clinical research to some of the world’s leading radiopharmaceutical organisations. Our story was well received but PowerPoint presentations and assumptions are the easy bit. Now we need to DELIVER (on Neuraceq sales) MAXIMISE (our product pipeline) and SUSTAIN (our world class research)! Challenging and Exciting. Making Life Better
-
FINAL REMINDER: Register now and save your spot to watch our live #webinar next Thursday, September 26th at 3pm EDT. Raymond Scott Turner and Kevin Berger will present the latest on the patient pathway from diagnostic workup to amyloid PET scanning and reimbursement. Click the link below for more details and to ensure your spot. If you cannot attend live, this webinar will be recorded for you to watch later. #amyloidPET #reimbursement #educationalwebinar #nuclearmedicine #alzheimersdisease #neurology #radiology #referringphysicians #imagingcenters #radiopharmaceuticals
Register Now
register.gotowebinar.com